For a patient handed a 30-day opioid script after surgery, the road to dependence often begins in a clinic, on a Tuesday morning, with a prescription that was never tapered down. That handoff, between the prescriber and the patient who keeps refilling, is what Reykjavik-based Prescriby is trying to redesign.
Founded in 2019 by Kjartan Thorsson, Prescriby sells a digital treatment management platform aimed at clinicians who prescribe addictive medications [Crunchbase]. The product pairs a treatment generator, which helps a clinician structure a tapering plan at the moment of prescribing, with a dashboard that monitors the patient's progress against that plan over time [Crunchbase].
The standard of care today leans heavily on the back end of the addiction pipeline. Once a patient is dependent, clinicians reach for medication-assisted treatment, behavioral therapy, and referrals to specialty addiction services. Prescription drug monitoring programs (PDMPs) exist in every U.S. state and in a growing number of European systems, but they function largely as databases that flag risky prescribing patterns after the fact rather than as decision tools at the moment a script is written. Prescriby's bet is that the highest-use intervention is upstream, at the prescription itself.
In April 2024, the company raised $2.1 million in a seed round led by Reykjavik-based Crowberry Capital [EU-Startups, April 2024]. Prescriby has also begun operating outside Iceland: the company set up a tapering clinic in Maine, an early U.S. foothold in a state that has been among the harder-hit by the opioid epidemic [Mainebiz].
| Metric | Value |
|---|---|
| Seed round (Apr 2024) | $2.1M |
This could matter because regulators and payers are pushing. The CDC's 2022 update to its opioid prescribing guideline reinforced individualized tapering and structured follow-up, and U.S. state attorneys general have continued to pressure health systems on prescribing discipline in the wake of opioid settlements. In Europe, the EMA and national regulators have grown more cautious about long-term opioid use. Software that sits inside the prescribing workflow, generates a defensible taper, and produces an audit trail of monitoring aligns with where guidelines and liability are heading.
Thorsson has built the company across an Icelandic and Canadian footprint, and the Maine clinic represents the first operational U.S. presence reported in the press [Mainebiz] [ArcticStartup]. The team is small and the company is at seed stage; public traction figures, peer-reviewed outcomes data, and named health-system customers have not been disclosed. What has been disclosed is a coherent product wedge, a lead investor with regional credibility, and a live U.S. deployment.
What bears will say is straightforward. Clinical software that tries to change prescriber behavior is historically slow to sell, hard to integrate with electronic health records, and difficult to prove out without controlled studies. The company has not, in the public record, pointed to peer-reviewed evidence that its specific intervention reduces transition to opioid use disorder. What bulls answer is that the regulatory and liability environment is doing some of the selling for them: post-settlement, U.S. health systems have a documented interest in being able to demonstrate disciplined opioid stewardship. The Maine clinic, if it generates real-world data on tapering completion and refill patterns, could be the wedge that converts the regulatory tailwind into clinical evidence [Mainebiz].
The next twelve months should clarify a few things. Watch for a published outcomes study or a named health-system pilot in the U.S. or Nordics. Watch the Maine clinic for any disclosed data on patient volumes and tapering outcomes. And watch for a Series A, which on the current $2.1 million seed would likely arrive in 2025 or 2026 if the company hits clinical and commercial milestones.